Roche: 9m sales up 5%.
(CercleFinance.com) - Roche reported consolidated sales of 39,434 million Swiss francs for the first nine months of 2017, up 5% at constant exchange rates and on a reported basis.
Pharmaceuticals sales rose by 5%, driven mainly by Ocrevus, Tecentriq and Perjeta, as well as by the diagnostics division, which grew by 5%, mainly due to the immunodiagnostic segment.
The Swiss healthcare group confirmed its annual targets, including mid-single-digit sales and adjusted EPS growth at constant exchange rates, and an increase in its dividend in Swiss francs.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Pharmaceuticals sales rose by 5%, driven mainly by Ocrevus, Tecentriq and Perjeta, as well as by the diagnostics division, which grew by 5%, mainly due to the immunodiagnostic segment.
The Swiss healthcare group confirmed its annual targets, including mid-single-digit sales and adjusted EPS growth at constant exchange rates, and an increase in its dividend in Swiss francs.
Copyright (c) 2017 CercleFinance.com. All rights reserved.